PMID- 9769115
OWN - NLM
STAT- MEDLINE
DCOM- 19981022
LR  - 20240426
IS  - 0340-7004 (Print)
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Linking)
VI  - 47
IP  - 2
DP  - 1998 Oct
TI  - Irradiated tumor cells adenovirally engineered to secrete 
      granulocyte/macrophage-colony-stimulating factor establish antitumor immunity and 
      eliminate pre-existing tumors in syngeneic mice.
PG  - 72-80
AB  - The specific aim of this study was to examine the prophylactic as well as the 
      therapeutic efficacies of irradiated mouse CT26 colon cancer cells, infected with 
      recombinant adenoviruses harboring cDNAs specific for granulocyte 
      macrophage-colony-stimulating factor (GM-CSF), interferon (IFN-gamma) and 
      monocyte chemotactic protein1 (MCP-1). Results showed that tumor cells secrete 
      the respective cytokines for several days after infection and subsequent 
      irradiation. Vaccination with irradiated GM-CSF-secreting CT26 cells protected 
      90% of syngeneic mice challenged with live parental cells. On the other hand, 
      vaccination with irradiated IFNgamma or MCP-1-secreting CT26 cells totally failed 
      to protect mice from tumor development after challenge with parental cells. None 
      of the tumor-free mice initially vaccinated with irradiated GM-CSF-producing CT26 
      cells developed tumor upon repeated challenge with parental cells during the 
      entire observation period. The establishment of specific and long-lasting 
      antitumor immunity following vaccination with GM-CSF-producing tumor cells 
      requires the simultaneous presence of GM-CSF and tumor antigen at the vaccine 
      site. Depletion of CD8+ cells, but not CD4+ cells, blocked the vaccine efficacy 
      of GM-CSF-producing tumor cells. Subcutaneous injection of irradiated 
      GM-CSF-producing CT26 cells also effectively prevented the growth of a small load 
      of parental tumor that was implanted 3 days earlier or the development of 
      metastatic foci in the lung from intravenously injected parental cells either 7 
      days before or 3 days after vaccination. Our data thus show that, in these 
      experimental tumor models, subcutaneous injection of irradiated tumor cells 
      adenovirally, transduced with the GM-CSF gene leads not only to prevention of 
      growth of subsequently implanted tumor but also to elimination of pre-existing 
      and metastatic tumors.
FAU - Nagai, E
AU  - Nagai E
AD  - Department of Microbiology, Molecular Genetics and Immunology, University of 
      Kansas Medical Center, Kansas City 66160-7420, USA.
FAU - Ogawa, T
AU  - Ogawa T
FAU - Kielian, T
AU  - Kielian T
FAU - Ikubo, A
AU  - Ikubo A
FAU - Suzuki, T
AU  - Suzuki T
LA  - eng
GR  - P01 CA54474/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Chemokine CCL2)
RN  - 0 (DNA, Complementary)
RN  - 82115-62-6 (Interferon-gamma)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
SB  - IM
MH  - 3T3 Cells/metabolism/virology
MH  - Adenoviridae/genetics
MH  - Animals
MH  - Antigens, Neoplasm/immunology/metabolism
MH  - CD4-Positive T-Lymphocytes/immunology
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - Cancer Vaccines/*genetics/*immunology/therapeutic use
MH  - Chemokine CCL2/genetics/immunology/metabolism
MH  - Colonic Neoplasms/*genetics/*metabolism/pathology
MH  - DNA, Complementary/genetics/metabolism
MH  - Female
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/genetics/*immunology/*metabolism
MH  - Immunotherapy/*methods
MH  - Interferon-gamma/genetics/immunology/metabolism
MH  - Lung Neoplasms/secondary/therapy
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Tumor Cells, Cultured/radiation effects
PMC - PMC11037337
EDAT- 1998/10/13 00:00
MHDA- 1998/10/13 00:01
PMCR- 1998/09/01
CRDT- 1998/10/13 00:00
PHST- 1998/10/13 00:00 [pubmed]
PHST- 1998/10/13 00:01 [medline]
PHST- 1998/10/13 00:00 [entrez]
PHST- 1998/09/01 00:00 [pmc-release]
AID - 80470072.262 [pii]
AID - 10.1007/s002620050506 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 1998 Oct;47(2):72-80. doi: 10.1007/s002620050506.